特布他林与阿奇霉素序贯疗法联合应用于小儿支原体肺炎治疗的效果分析与评价

Effect of Terbutaline Combined with Azithromycin Sequential Therapy on Children with Mycoplasmal Pneumonia

目的观察特布他林与阿奇霉素序贯疗法联合应用于小儿支原体肺炎治疗中的效果。方法将2017年10月—2018年10月在该院接受治疗的230例支原体肺炎患儿随机分为实验组(n=115)和对照组(n=115)。对照组采取阿奇霉素序贯疗法,实验组在对照组的基础上加用特布他林治疗。比较两组患儿的治疗1个疗程后的临床疗效及炎性因子水平。结果治疗后,实验组治疗总显效率明显高于对照组(80.87%vs60.87%)C反应蛋白、白介素-6及肿瘤坏死因子-α水平低于对照组[(7.06±0.98)mg/Lvs(12.36±1.52)mg/L,(9.72±3.64)ng/Lvs(16.33±4.85)ng/L,(20.01±4.67)ng/Lvs(28.81±5.07)ng/L](χ^2=11.141,t=31.427,11.689,13.691P<0.05)。结论特布他林与阿奇霉素序贯疗法联合有利于提高支原体肺炎患儿的治疗效果。

Objective To observe the effect of terbutaline combined with azithromycin sequential therapy on children with mycoplasmal pneumonia.Methods 230 children with mycoplasmal pneumonia who were treated in our hospital from October 2017 to October 2018 were randomly divided into two groups.The control group was treated with azithromycin sequential therapy.The experimental group was treated with terbutaline on the basis of the control group.The clinical efficacy and inflammatory factor levels were compared between the two groups after 1 courses of treatment.Results After treatment,the effective rate of the experimental group was significantly higher than that of the control group (80.87% vs 60.87%).The levels of inflammatory factors in the experimental group were lower than those in the control group [CRP,IL-6 and TNF-α levels:(7.06±0.98)mg/L vs (12.36±1.52)mg/L,(9.72±3.64)ng/L vs (16.33±4.85)ng/L,(20.01±4.67)ng/L vs (28.81±5.07)ng/L], all the above differences were significant(χ^2=11.141,t=31.427,11.689,13.691,P<0.05).Conclusion The combination of terbutaline and azithromycin sequential therapy is beneficial to improve the clinical efficacy of children with mycoplasmal pneumonia.